155 related articles for article (PubMed ID: 28067434)
1. Pioglitazone and bladder cancer: FDA's assessment.
Hampp C; Pippins J
Pharmacoepidemiol Drug Saf; 2017 Feb; 26(2):117-118. PubMed ID: 28067434
[No Abstract] [Full Text] [Related]
2. A word of caution regarding pioglitazone.
Usman MS; Rizwan T; Ahmed F
J Pak Med Assoc; 2017 Jan; 67(1):153. PubMed ID: 28065979
[No Abstract] [Full Text] [Related]
3. Global Versus Indian Perspective of Pioglitazone-induced Adverse Drug Reactions Including Bladder Cancer: A Comparative Retrospective Pharmacovigilance Analysis.
Bhushan S; Ray RS; Prakash J; Singh GN
Clin Ther; 2019 Nov; 41(11):2252-2262. PubMed ID: 31543285
[TBL] [Abstract][Full Text] [Related]
4. The impact of pioglitazone on bladder cancer and cardiovascular events.
Lee EJ; Marcy TR
Consult Pharm; 2014 Aug; 29(8):555-8. PubMed ID: 25203263
[TBL] [Abstract][Full Text] [Related]
5. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting.
Piccinni C; Motola D; Marchesini G; Poluzzi E
Diabetes Care; 2011 Jun; 34(6):1369-71. PubMed ID: 21515844
[TBL] [Abstract][Full Text] [Related]
6. Pioglitazone and bladder cancer: two studies, same database, two answers.
de Vries F; Zeegers M; Goossens ME
Br J Clin Pharmacol; 2013 Sep; 76(3):484-5. PubMed ID: 23617237
[No Abstract] [Full Text] [Related]
7. Association between pioglitazone and urothelial bladder cancer.
Barbalat Y; Dombrovskiy VY; Weiss RE
Urology; 2012 Jul; 80(1):1-4. PubMed ID: 22626574
[TBL] [Abstract][Full Text] [Related]
8. Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes.
Garry EM; Buse JB; Gokhale M; Lund JL; Nielsen ME; Pate V; Stürmer T
Diabetes Obes Metab; 2019 Sep; 21(9):2096-2106. PubMed ID: 31087620
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of observational studies of the association between pioglitazone use and bladder cancer.
Ripamonti E; Azoulay L; Abrahamowicz M; Platt RW; Suissa S
Diabet Med; 2019 Jan; 36(1):22-35. PubMed ID: 30378165
[TBL] [Abstract][Full Text] [Related]
10. Examples of how the pharmaceutical industries distort the evidence of drug safety: the case of pioglitazone and the bladder cancer issue.
Faillie JL; Hillaire-Buys D
Pharmacoepidemiol Drug Saf; 2016 Feb; 25(2):212-4. PubMed ID: 26617411
[No Abstract] [Full Text] [Related]
11. Pioglitazone and bladder cancer risk: a systematic review and meta-analysis.
Tang H; Shi W; Fu S; Wang T; Zhai S; Song Y; Han J
Cancer Med; 2018 Apr; 7(4):1070-1080. PubMed ID: 29476615
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities?
Tseng CH
J Formos Med Assoc; 2012 Mar; 111(3):123-31. PubMed ID: 22423665
[TBL] [Abstract][Full Text] [Related]
13. FDA's first active medical product surveillance eyes antidiabetic-MI link.
Thompson CA
Am J Health Syst Pharm; 2011 Apr; 68(7):550-1. PubMed ID: 21411791
[No Abstract] [Full Text] [Related]
14. Pioglitazone use and the risk of bladder cancer.
Kuo HW; Tiao MM; Ho SC; Yang CY
Kaohsiung J Med Sci; 2014 Feb; 30(2):94-7. PubMed ID: 24444539
[TBL] [Abstract][Full Text] [Related]
15. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies.
Ferwana M; Firwana B; Hasan R; Al-Mallah MH; Kim S; Montori VM; Murad MH
Diabet Med; 2013 Sep; 30(9):1026-32. PubMed ID: 23350856
[TBL] [Abstract][Full Text] [Related]
16. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis.
Zhu Z; Shen Z; Lu Y; Zhong S; Xu C
Diabetes Res Clin Pract; 2012 Oct; 98(1):159-63. PubMed ID: 22705039
[TBL] [Abstract][Full Text] [Related]
17. Pioglitazone use in Australia and the United Kingdom following drug safety advisories on bladder cancer risk: An interrupted time series study.
Kemp-Casey A; Mintzes B; Morrow RL; Dormuth CR; Souverein PC; Roughead EE
Pharmacoepidemiol Drug Saf; 2022 Oct; 31(10):1039-1045. PubMed ID: 35790047
[TBL] [Abstract][Full Text] [Related]
18. Global and Regional Effects of Bladder Cancer Risk Associated with Pioglitazone Therapy in Patients with Diabetes.
Qu H; Zheng Y; Wang Y; Zhang R; Ruan X; Yang G; Liu Z; Zheng H
Sci Rep; 2017 Nov; 7(1):15804. PubMed ID: 29150684
[TBL] [Abstract][Full Text] [Related]
19. Diabetes drug may be associated with increase in risk of bladder cancer.
Stephenson J
JAMA; 2011 Jul; 306(2):143. PubMed ID: 21750286
[No Abstract] [Full Text] [Related]
20. Association between pioglitazone use and the risk of bladder cancer among subjects with diabetes mellitus: a dose-response meta-analysis
.
Li Z; Sun M; Wang F; Shi J; Wang K
Int J Clin Pharmacol Ther; 2017 Mar; 55(3):210-219. PubMed ID: 28025963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
